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OBJECTIVE: The aim of the present study was to evaluate the autonomic modulation of the cardiovascular system in streptozotocin
(STZ)-induced diabetic spontaneously hypertensive rats (SHR), evaluating baroreflex sensitivity and arterial pressure and heart rate
variability.
METHODS: Male SHR were divided in control (SHR) and diabetic (SHR+DM, 5 days after STZ) groups. Arterial pressure (AP)
and baroreflex sensitivity (evaluated by tachycardic and bradycardic responses to changes in AP) were monitored. Autoregressive
spectral estimation was performed for systolic AP (SAP) and pulse interval (PI) with oscillatory components quantified as low
(LF:0.2-0.6Hz) and high (HF:0.6-3.0Hz) frequency ranges.
RESULTS: Mean AP and heart rate in SHR+DM (131±3 mmHg and 276±6 bpm) were lower than in SHR (160±7 mmHg and
330±8 bpm). Baroreflex bradycardia was lower in SHR+DM as compared to SHR (0.55±0.1 vs. 0.97±0.1 bpm/mmHg). Overall
SAP variability in the time domain (standard deviation of beat-by-beat time series of SAP) was lower in SHR+DM (3.1±0.2
mmHg) than in SHR (5.7±0.6 mmHg). The standard deviation of the PI was similar between groups. Diabetes reduced the LF of
SAP (3.3±0.8 vs. 28.7±7.6 mmHg2 in SHR), while HF of SAP were unchanged. The power of oscillatory components of PI did not
differ between groups.
CONCLUSIONS: These results show that the association of hypertension and diabetes causes an impairment of the peripheral
cardiovascular sympathetic modulation that could be, at least in part, responsible for the reduction in AP levels. Moreover, this
study demonstrates that diabetes might actually impair the reduced buffer function of the baroreceptors while reducing blood
pressure.
KEYWORDS: Hypertension. Diabetes. Spectral Analysis. Cardiovascular Function. Baroreflex Sensitivity.
INTRODUCTION
Diabetes mellitus (DM) is a worldwide health problem,
because its prevalence has been on the rise during the past
few decades and because of the high levels of morbidity and
mortality of this disease. The high morbidity and mortality
of DM is derived from chronic micro and macrovascular
complications,1 as well as alterations in the autonomic neu-
ral control of the cardiovascular system.2,3 Autonomic neu-
ropathy is a common complication of DM that has been found
not only in clinical but also in animal models of DM.2,4 Stud-
ies performed in our laboratory on streptozotocin (STZ)-in-
duced diabetic rats showed that they present long-lasting
changes in blood pressure, heart rate and autonomic cardio-
vascular reflexes.5-8 Using a pharmacological blockade, we
demonstrated a reduction in vagal tone and maintenance of
sympathetic tone to the heart, suggesting the presence of car-
478
CLINICS 2007;62(4):477-82Autonomic modulation of arterial pressure and heart rate variability in hypertensive diabetic rats
Farah VMA et al.
diac vagal neuropathy in STZ-induced DM.6,9
Several methods have been introduced to evaluate car-
diac autonomic neuropathy in clinical and experimental
diabetes. Methods to quantify heart rate and arterial pres-
sure variability have emerged as useful tools to evaluate
sympathetic a parasympathetic modulation of the cardio-
vascular system in humans10 and experimental models.11-15
These methods are able to detect early abnormalities in the
autonomic modulation of the cardiovascular system.16-19
When evaluated in the time domain, the heart rate variabil-
ity was reduced in chronic STZ-diabetic rats.12,20 In another
study, Fazan et al.19 observed reduction in the arterial pres-
sure (AP) and heart rate (HR) variability, measured either
as the standard deviation or by spectral analysis in chronic
STZ-diabetic rats. In humans with DM, spectral analysis
of HR disclosed significant changes in the cardiovascular
variability in the frequency domain, which were apparent
even before changes in all other standard cardiovascular
parameters.17
Administration of STZ is a well-established method to
induce diabetes in rodents,21 producing a number of car-
diovascular changes such as hypotension, bradycardia, de-
creased AP variability, and impairment of the reflex con-
trol of circulation.4,19,22,23 Since the administration of STZ
to Wistar rats induces a diabetic state that is not accompa-
nied by hypertension,11 its use in spontaneously hyperten-
sive rats (SHR) can produce an animal model more closely
related to human diabetes. Therefore, the aim of the present
study was to evaluate the autonomic modulation of the car-
diovascular function in STZ-induced diabetic SHR, by
studying the blood pressure and heart rate variability in the
time and frequency domains (spectral analysis), and also
evaluating the cardiac baroreflex sensitivity in this model.
MATERIALS AND METHODS
Experiments were performed in male SHR weighing
250-270g. The animals were housed in individual cages
with free access to water and food, at a constant tempera-
ture of 23oC, on a 12-hour light/dark cycle. All experimental
protocols were in accordance with the Guidelines for Ethi-
cal Care of Experimental Animals and were approved by
the Institutional Animal Care and Use Committee.
Diabetes was induced by a single injection of STZ (50 mg/
kg, i.v., Sigma Chemical Co, St Louis, MO, USA) dissolved
in 0.01 M citrate buffer, pH 4.5, administered 5 days before
the experiments in SHR (SHR+DM, n=7). The control SHR
group (SHR, n=7) was injected with citrate buffer alone. The
rats were fasted for 8h before STZ or vehicle injection.21
One day before the experiments, arterial and venous
catheters were placed in the right femoral artery and vein
under sodium pentobarbital anesthesia (40 mg/kg, IP,
Cristalia, SP, Brazil) for the direct measurement of AP and
drug administration, respectively. The catheters were ex-
teriorized through the back of the neck.
The experiments consisted in continuously recording AP
(30 minutes) via a transducer (P23Db, Gould-Statham) con-
nected to the arterial catheter. Rats were conscious and moved
freely during the experiments. The signal was fed into an am-
plifier (GPA-4 model 2, Stemtech Inc.) and a 16-channel ana-
log-to-digital interface, and continuously sampled (2 kHz) in
an IBM/PC. Increasing doses of phenylephrine (0.05 to 0.8
µg/kg) and sodium nitroprusside (5 to 20 µg/kg) were given
as sequential bolus injections (0.1 mL) to produce changes in
AP ranging from 5 to 30 mmHg. Injections were not repeated
until the recorded parameters had returned to pre-injection lev-
els. Then, beat-to-beat values of systolic, diastolic and mean
AP were identified and HR or pulse interval (PI) was calcu-
lated as the interval between successive systolic pressure val-
ues by using the computer software CODAS (Dataq, Inc).
Baroreflex sensitivity, expressed as bpm/mmHg, was
evaluated by means of the index relating reflex changes in
HR due to the changes in mean AP (MAP), as described
elsewhere.24 At the end of the AP recordings, a blood sam-
ple was collected for glucose measurement (Advantage,
Roche, Indianapolis, IN, USA) and then the animals were
killed by pentobarbital overdose.
The overall variability of the PI and systolic AP (SAP)
in the time domain was assessed by the standard deviation
of the time series. Furthermore, PI and SAP fluctuations
were assessed in the frequency domain by means of
autoregressive spectral estimation. The theoretical and ana-
lytical procedures for autoregressive modeling of oscillatory
components have been fully described previously.10,13-15,25,26
Briefly, the PI and SAP series derived from each recording
were divided into 300-beat segments with a 50% overlap.
The spectra of each segment were calculated via the
Levinson-Durbin recursion, and the order of the model cho-
sen according to Akaike’s criterion, with the oscillatory
components quantified in low (LF: 0.2 to 0.6 Hz) and high
frequency (HF: 0.6 to 3.0 Hz) ranges.
Data are presented as mean ± SEM. Comparisons between
the two groups were performed using Student’s unpaired t tests.
Pearson correlation was used to study association between vari-
ables. The significance level was established as P < 0.05.
RESULTS
Blood glucose levels were remarkably higher (p<0.05)
in SHR+DM (248±23 mg/dL) as compared to SHR (86±5.5
mg/dL), showing the efficacy of the experimental diabetes
induction. Body weight was significantly lower (p<0.05) in
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the diabetic (214±2 g) compared to the non-diabetic SHR
group (255±4 g, p<0.05).
Diabetic-SHR showed lower MAP and HR (131±3
mmHg and 276±6 bpm) as compared to SHR (160±7
mmHg and 330±8 bpm). Reflex bradycardic response to
phenylephrine administration was also lower in SHR+DM
(0.55±0.10 bpm/mmHg) than in SHR (0.97±0.10 bpm/
mmHg, Figure 1B). Nevertheless, no differences were found
in the reflex tachycardia elicited by decreasing MAP due
to sodium nitroprusside in both groups (1.55±0.20 vs.
1.54±0.26 bpm/mmHg, for SHR+DM and SHR, respec-
tively) (Figure 1B). Correlation analysis involving all ani-
mals showed a significant inverse relationship between re-
flex bradycardia sensitivity and the blood glucose level (r
= 0.70, p < 0.01, Figure 1D).
The standard deviation of PI did not differ between the
groups studied (6.2±0.7 vs. 4.9±0.3 ms, for SHR+DM and
SHR, respectively). On the other hand, the standard devia-
tion of SAP was lower in SHR+DM (3.1±0.2 mmHg) as
compared to the SHR (5.7±0.6 mmHg, p<0.05) (Figure 1A).
Figure 2 shows representative spectra of PI and SAP from
each group. As expected, the spectra presented two distinct
oscillatory components, one in low (~ 0.4 Hz) and one in
high (~ 1.5 Hz) frequency bands. The magnitude of the os-
cillations for each group is described in Table 1. We found
no differences in the power of the oscillatory components
in the PI spectra either for SHR+DM and SHR. Neverthe-
less, the SAP LF oscillation of the SHR+DM group was re-
markably attenuated (~85%) as compared to SHR (Table 1
and Figure 1A). There was no difference in HF oscillations
of SAP between groups. Furthermore, the power of the SAP
LF component was inversely correlated to the blood glucose
level (r = 0.63, p<0.05, Figure 1C), indicating a clear rela-
tionship between increased blood glucose and the power of
the LF component of the SAP spectrum.
DISCUSSION
This study demonstrated that the induction of diabetes
in the SHR enhances abnormalities usually seen in both ani-
mal models individually, i.e. spontaneous hypertension and
STZ-induced diabetes. Using spectral analysis approaches,
we found decreased arterial pressure variability in STZ-
treated SHR. Moreover, the well-documented impairment of
Figure 1: A- Average values of power spectral density (mmHg2) in the low
(LF:0.2-0.6Hz) and high (HF:0.6-3.0Hz) frequency bands of systolic arterial
pressure variability in SHR (white bars) and SHR+DM (black bars); B-
Baroreflex index (bpm/mmHg) of bradycardic (BR) and tachycardic (TR)
responses to arterial pressure changes in SHR (white bars) and SHR+DM (black
bars); C- Negative correlation obtained by linear regression between power of
low-frequency of systolic arterial pressure (LF-SAP, mmHg2) and glycemia
(mg/dL) using data from both groups; D- Negative correlation obtained by
linear regression between the bradycardic response (BR, bpm/mmHg) and
glycemia (mg/dL) using data from both groups. *P<0.05 SHR vs. SHR+DM.
Table 1. Spectral parameters of pulse interval (PI) and systolic
arterial pressure (SAP) variabilities in non-diabetic (SHR)
and in diabetic spontaneously hypertensive rats (SHR+DM).
PI SHR (n=07) SHR+DM (n=07)
LF peak (Hz) 0.39±0.03 0.55±0.03
LF absolute (ms2) 1.5±0.8 1.0±0.2
LF (%) 7.2±3.1 4.3±0.8
HF peak (Hz) 1.51±0.07 1.41±0.03
HF absolute (ms2) 15.7±2.0 29.1±7.2
HF (%) 92.8±3.1 95.7±0.8
SAP
LF peak (Hz) 0.34±0.02 0.41±0.02
LF absolute (mmHg2) 28.2±7.6 3.30±0.8*
LF (%) 81.0±4.6 42.1±6.4*
HF peak (Hz) 1.51±0.08 1.41±0.03
HF absolute (mmHg2) 4.1±0.6 3.5±0.3
HF (%) 19.0±4.6 57.9±6.4*
Values are mean ± SEM. LF = low frequency; HF = high frequency. *
P<0.05 vs. non-diabetic SHR.
Figure 2: Spectra of PI (top, ms2/Hz) and SAP (bottom, mmHg2/Hz) variability
in one representative animal of the SHR and SHR+DM groups.
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heart rate baroreflex control previously observed in SHR27
further depressed in diabetic-hypertensive rats.
Although of short duration (5 days), the diabetic state
induced by STZ in spontaneously hypertensive rats pro-
duced hyperglycemia associated with a decrease in body
weight. As previously described in normotensive rats,5-9,11,20
STZ treatment led to a decreased MAP and HR. However,
in the present study, blood pressure values were still kept
at hypertensive levels in the diabetic-SHR. The mechanisms
involved in these alterations have not been completely un-
derstood. Osmotic diuresis causing hypovolemia or myo-
cardial dysfunction reducing contractile force are putative
mechanisms of the lower blood pressure observed in the
normotensive STZ-diabetic rat.9,28,29 The recent observation
of enhanced endothelium-dependent vasodilation due to
increased production of prostaglandin I2 and endothelium-
derived hyperpolarizing factor in short-term STZ-diabetic
mice is another mechanism that could contribute to hypo-
tension in this similar animal model.30
The bradycardia found in SHR+DM may be related to
decreased sympathetic nerve activity and/or reduced den-
sity of myocardial b-adrenergic receptors, as well as to func-
tional changes in cardiac cholinergic mechanisms,31,32 al-
though these authors did not study hypertensive animals,
as we did. Indeed, studies from our laboratory performing
vagal and sympathetic blockade suggest changes in basal
spontaneous pacemaker.6 There is evidence suggesting that
both sympathetic and parasympathetic function to the heart
were reduced after STZ administration.6
In analyzing the alterations that occurred in arterial
pressure and heart rate variability using spectral analysis
approaches, we observed that the heart rate variability did
not change with short-term STZ treatment in hypertensive
rats. In fact, decreased heart rate variability has been re-
ported only after long-lasting diabetes in normotensive rats
using either time domain or spectral analysis.12,19,20 On the
other hand, we showed reduced arterial pressure variabil-
ity in the SHR+DM, with reduction in the standard devia-
tion (~67%) and also in the power of the low frequency os-
cillations of SAP (~85%). Similarly, we have previously
demonstrated decreased MAP variability in experimental
normotensive diabetic rats.11,23 It is well-known that in hu-
mans and in rat animal models, the low frequency oscilla-
tions of blood pressure correspond to the influence of the
sympathetic fibers acting on the cardiovascular system.16,33,34
This reduced sympathetic influence on blood vessels could
explain, at least in part, the lower blood pressure and its
variability found in this SHR+DM group.
Moreover, changes in the low frequency oscillations may
be related to alterations in baroreflex function.35 Indeed, our
data show that diabetes induced a blunted baroreflex-medi-
ated bradycardia in hypertensive rats, whereas reflex tachy-
cardia remained unchanged. It is well known that spontane-
ous hypertension in rats is associated with a depressed
baroreflex control of heart rate not only during MAP in-
creases, but also during MAP decreases.27 This study dem-
onstrated, for the first time, that diabetes might even further
impair the reduced buffer function of the baroreceptors while
reducing blood pressure.
The inverse correlation observed between either reflex
bradycardic sensitivity or the power of LF oscillations of SAP
and blood glucose levels reinforce the crucial role of metabolic
changes in cardiovascular disorders in this animal model. Our
laboratory observed similar results in a previous study, which
demonstrated that heart rate and MAP variability were strongly
correlated with urinary and plasmatic glucose.11,23
Sympathetic hyperactivity associated with reduced car-
diac vagal function and blunted baroreflex sensitivity has
been shown in SHR,27,36 while depressed baroreflex sensi-
tivity and changes in intrinsic heart rate have been reported
in STZ-diabetic rats.5,6 In the present study, the association
of hypertension and diabetes seemed not to significantly
change the previously observed impairment of the cardiac
function in normotensive diabetic rats.4 In fact, Balbinott
et al.20 showed that diabetes associated with hypertension
induced by nitric oxide blockade determined similar results
in cardiovascular system. Thus, the cardiovascular deficit
observed in hypertensive-diabetic animals can be attributed
at least in part to changes in the nitric oxide system. In-
deed, in contrast to the usually observed increase in the ar-
terial pressure variability of hypertension, diabetes induced
a marked decrease in blood pressure variability. These re-
sults are in agreement with the concept that, in hyperten-
sion, there might be a shift in autonomic drive in favor of
sympathetic excitatory drive mechanisms that was reduced
by diabetes.26 In this context, the significant inverse corre-
lation between the systolic arterial pressure LF and blood
glucose values observed in the present study supports the
idea that the metabolic derangement of diabetes, in asso-
ciation with hypertension, is associated with autonomic dys-
function and cardiovascular impairment characterized by
the uncoupling of heart rate and blood pressure. These find-
ings cannot exclude, however, the participation of other cen-
tral or peripheral control mechanisms in the pathophysiol-
ogy of hypertension and diabetes association.
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RESUMO
276±6 bpm) em relação ao grupo SHR (160±7 mmHg e
330±8 bpm). A bradicardia reflexa a aumentos de PA es-
tava atenuada no grupo SHR+DM quando comparada ao
grupo SHR (0,55±0,1 vs 0,97±0,1 bpm/mmHg). A varia-
bilidade da PAS no domínio do tempo (desvio padrão
batimento-a-batimento da série temporal da PAS) foi me-
nor no grupo SHR+DM (3,1±0,2 mmHg) quando compa-
rada ao grupo SHR (5,7±0,6 mmHg). O desvio padrão do
IP foi semelhante entre os grupos. O diabetes reduziu o
componente BF da PAS (3,3±0,8 vs 28,7±7,6 mmHg2 no
SHR), mas não alterou o componente AF da PAS. Em re-
lação aos componentes oscilatórios do IP não houve dife-
rença entre os grupos.
CONCLUSÕES: Estes resultados sugerem que a associação
de hipertensão e diabetes causa uma importante diminuição da
modulação simpática cardiovascular periférica que poderia, pelo
menos em parte, ser responsável pela redução da PA. Além dis-
so, este estudo demonstra que o diabetes pode, de fato, piorar
a já reduzida função de tamponamento dos barorreceptores ao
mesmo tempo em que reduz a pressão arterial.
UNITERMOS: Hipertensão. Diabetes. Análise Espectral.
Função Cardiovascular. Sensibilidade do Barorreflexo.
Farah VMA, De Angelis K, Joaquim LF, Candido GO,
Bernardes N, Fazan Jr R, Schaan BD, Irigoyen MC.
Modulação autonômica da pressão arterial e variabilidade
da freqüência cardíaca em ratos hipertensos e diabéticos.
CLINICS. 2007;62(4):477-82.
OBJETIVO: O objetivo do presente estudo foi investigar
a modulação autonômica do sistema cardiovascular em ra-
tos espontâneamente hipertensos (SHR) e diabéticos por
estreptozotocina (STZ), avaliando a sensibilidade do reflexo
barorreceptor e a variabilidade da pressão arterial e da fre-
qüência cardíaca.
MÉTODOS: Ratos SHR machos foram divididos em gru-
pos controle (SHR) e diabéticos (SHR+DM, 5 dias após
STZ). A pressão arterial (PA) e a sensibilidade dos
barorreceptores (avaliada pelas respostas taquicárdicas e
bradicárdicas a alterações da PA) foram monitoradas. Os
sinais de pressão arterial sistólica (PAS) e o intervalo de
pulso (IP) foram analisados no domínio do tempo e da fre-
qüência pelo método autoregressivo sendo quantificados os
componentes oscilatórios de baixa (BF: 0,2-0,6Hz) e alta
(AF:0,6-3,0Hz) freqüência.
RESULTADOS: A PA média e a freqüência cardíaca es-
tavam reduzidas no grupo SHR+DM (131±3 mmHg e
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